Almirall (ALM.MC) Stock Price
Almirall Price
Over the last 19 years Almirall grew revenue by 1.8% annually, reaching 1.11 B EUR. Earnings per share have declined at 7.2% per year over the last 19 years. For Almirall, the net margin of 4.2% is up versus -4.9% a few years ago. At today's price the dividend yield works out to roughly 1.64%. The payout ratio is around 85% of earnings. The consensus 12-month price target for Almirall is 14.28 EUR, about 27.3% above where the stock trades today. Of 17 analysts, 12 rate the stock a buy — an overall Buy consensus.
Almirall stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Almirall business model & stock analysis
Frequently asked questions about Almirall
The business model of Almirall SA focuses on the pharmaceutical industry. Almirall SA is a global biopharmaceutical company that specializes in the research, development, and commercialization of innovative medicines. They operate primarily in the fields of dermatology, gastroenterology, and respiratory diseases, offering a diversified portfolio of pharmaceutical products. Almirall SA aims to meet patient needs by delivering high-quality and effective medicines while maintaining a strong commitment to research and development. Through strategic partnerships and collaborations, Almirall SA strives to improve the health and well-being of people worldwide with their innovative solutions.
Almirall SA is primarily active in the pharmaceutical industry.
The main competitors of Almirall SA in the market include prominent pharmaceutical companies such as AstraZeneca, Novartis, Johnson & Johnson, and GlaxoSmithKline.
Almirall SA, a leading pharmaceutical company, has a rich history and a strong background. Founded in 1943 in Barcelona, Spain, Almirall has been dedicated to improving people's health and well-being for over 75 years. The company specializes in researching, developing, manufacturing, and marketing innovative medicines and healthcare solutions worldwide. With a commitment to scientific excellence and a customer-centric approach, Almirall has established itself as a trusted name in the pharmaceutical industry. Continuously expanding its product portfolio and collaborating with valued partners, Almirall strives to meet the evolving needs of patients and healthcare professionals, driving advancements and reshaping the future of healthcare.
Almirall SA has achieved several significant milestones in its corporate history. Over the years, the company has successfully developed and marketed innovative pharmaceutical products. Notably, Almirall SA has gained regulatory approvals for a range of therapeutic solutions, such as dermatology treatments and respiratory medicines. The company has also expanded its global presence and entered into strategic partnerships to enhance its research and commercial capabilities. Almirall SA continues to strive for excellence in the healthcare industry, focusing on the development of novel therapies to improve patients' lives and maintain its position as a leading pharmaceutical company.
Almirall SA is primarily present in various countries and regions worldwide. The company has a significant presence in Europe, including Spain, where it is headquartered. Additionally, Almirall SA operates in several countries across the Americas, including Mexico, Brazil, and Colombia. The company also has a growing presence in Asia, particularly in China and Japan. Almirall SA's global reach enables it to serve a diverse customer base and leverage different market opportunities.
Almirall SA represents values of innovation, integrity, and excellence in the pharmaceutical industry. The company is committed to improving patients' lives by developing and providing effective and safe medical solutions. Almirall SA strives for scientific advancement and collaboration to address unmet medical needs. With a strong corporate philosophy focused on patient-centricity and sustainability, Almirall SA aims to deliver high-quality healthcare products and services worldwide. Through its dedication to research and development, this global pharmaceutical company seeks to make a positive impact on patients, healthcare professionals, and society as a whole.
Analysts currently set an average price target of 14.22 EUR for the Almirall stock (median: 14.28 EUR), implying +27.9 % versus the latest price. The consensus is based on 17 analyst ratings.
17 analysts currently rate the Almirall stock: 12 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Almirall to generate revenue of 1.23 B EUR and earnings per share of 0.37 EUR.
The Almirall share (ALM.MC) is listed on 8 stock exchanges, including: London (0O9B.L), Frankfurt (E2Z.F), München (E2Z.MU), Düsseldorf (E2Z.DU), Madrid (ALM.MC).
Almirall SA is a pharmaceutical company based in Spain. The company focuses on researching and developing medications for the treatment of respiratory and dermatology conditions, as well as pain and inflammatory diseases.
The expected revenue of Almirall is 1.23 B EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Almirall is 78.96 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Almirall is currently 30.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Almirall stock.
The price-to-sales ratio (P/S) of Almirall is currently 1.96. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Almirall stock.
The Eulerpool Quality Score for Almirall is 4/10.
The ISIN of Almirall is ES0157097017. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Almirall is A0MU8Y. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Almirall is ALM.MC. The ticker symbol is used to trade Almirall shares on the stock exchange.
Almirall stock
Almirall Peer Group
Almirall Ticker
Almirall FIGI
All fundamentals and in-depth analysis of Almirall
Our stock analysis for Almirall stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Almirall. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.